Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati32

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati19

Views

Views
October 20240
November 20240
December 20240
January 20251
February 20253
March 202515
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States3
United Kingdom1
 

Top cities views

Views
Buffalo1
Pasadena1